Skip to main navigation Skip to search Skip to main content

How advances in immunology provide insight into improving vaccine efficacy

Research output: Contribution to journalReview articlepeer-review

Abstract

Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.

Original languageEnglish (US)
Pages (from-to)2948-2957
Number of pages10
JournalVaccine
Volume32
Issue number25
DOIs
StatePublished - May 23 2014

Funding

This project was funded in part with federal funds from the National Institute of Allergy and Infectious Diseases , R44 AI079898 (to MKS and IJA), R01 AI098723 (to MKS) and Oregon National Primate Research Center grant , 8P51 OD011092-53 (to MKS). OHSU, Dr. Slifka, and Dr. Amanna have a financial interest in Najít Technologies, Inc., a company that is developing new vaccines using a hydrogen peroxide-based inactivation approach. This potential individual and institutional conflict of interest has been reviewed and managed by OHSU.

FundersFunder number
National Institute of Allergy and Infectious DiseasesR44 AI079898, R01AI098723
Oregon National Primate Research Center8P51 OD011092-53

    Keywords

    • Antibody
    • Immunological memory
    • Protection
    • Vaccination

    ASJC Scopus subject areas

    • Molecular Medicine
    • General Immunology and Microbiology
    • General Veterinary
    • Public Health, Environmental and Occupational Health
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'How advances in immunology provide insight into improving vaccine efficacy'. Together they form a unique fingerprint.

    Cite this